Innocan notes article on LPT-CBD injections in goats

Executive Summary

• Innocan Pharma Corp. announced the publication of a peer-reviewed study in Frontiers in Pharmacology demonstrating promising translational evidence for its LPT-CBD technology in pain relief.
• The study involved two goats with chronic pain treated with subcutaneous synthetic liposomal cannabidiol (LPT-CBD) injections every six weeks for 10 months.
• Results indicated sustained pain relief, improved mobility, and enhanced quality of life, with no adverse events or elevation of liver enzyme markers, suggesting a favorable long-term safety profile compared to oral CBD.

Key Details

• Publication: Article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats" published in Frontiers in Pharmacology.
• Study Design: Two goats with chronic, disabling painful conditions received subcutaneous LPT-CBD injections (5 mg/kg) every six weeks for a duration of 10 months.
• Total Doses: Seven injections per goat.
• Pharmacokinetics: Repeated injections maintained sustained CBD plasma concentrations consistent with a slow-release profile.
• Safety Profile:
  • No recorded adverse events throughout the study.
  • Unlike repeated oral CBD consumption in humans, repeated LPT-CBD injections did not elevate liver enzyme markers typically associated with liver injury.
• Efficacy Outcomes:
  • Sustained pain relief.
  • Improved mobility.
  • Enhanced quality of life, consistently maintained over the 10-month period.
• Clinical Implications: The study suggests LPT-CBD injections every six weeks are practical, provide long-term plasma concentrations, and offer potential for non-opioid chronic pain therapy in humans.

Notable Quotes

• Prof. Chezy Barenholz, Head of Advisory Board: "The findings of this study highlight the sustained beneficial effects of LPT-CBD observed over 10 months of repeated administration... LPT-CBD was designed for the treatment of chronic conditions through repeated monthly administrations, and this study provides promising translational evidence supporting this approach."
• Dr. Eyal Kalo, Vice-President of Research and Development: "This study demonstrates that repeated LPT-CBD administration, designed as a non-opioid chronic pain therapy, does not elevate liver enzymes, supporting a favourable long-term safety profile. By comparison, repeated oral CBD intake has been linked to elevated liver enzymes and potential liver injury. These results strengthen the evidence supporting the long-term safety of LPT-CBD in humans."